Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NTTG who wrote (12037)	6/10/2013 12:44:51 PM
From: Mimbari	Read Replies (1) \| Respond to of 13111

So I asked. He says there is no one answer. When treating the patient many factors have to be considered. BECAUSE the treated tumor dies off at a quick pace then the total amount of necrotic tumor burden must be taken into account. Condition of the kidneys and liver must be known as too much necrotic tissue being filtered could cause those organs to be damaged. Beginning trial dosage started at the historical dosages that rose bengal was used as a diagnostic agent and moved up from there. Maximum dosage depends on tumor size that can handled by the body.